Developer docs
API playgroundTry for free, no card

Search company profiles

EVER Pharma

Full company profile

uuid0008fp5

Namestring
EVER Pharma
Legal namestring
EVER Neuro Pharma GmbH
Websiteurl
everpharma.com
Company typeenum
Private
Founded yearint
1934
Descriptiontext

EVER Pharma is a privately held, family-owned specialty pharmaceutical company founded in 1934 and headquartered in Unterach, Austria. The company develops, manufactures, and commercializes a portfolio of branded specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Its product range includes differentiated formulations such as room-temperature-stable Fulvestrant (the first in Europe), ready-to-use liquid Bortezomib, single-vial Cabazitaxel, and a complete Parkinson's disease therapy package combining Apomorphine (Dacepton) with proprietary micro-infusion devices (D-mine Pump, D-mine Pen). Manufacturing is concentrated in two EU GMP-certified facilities: the Unterach headquarters and R&D center (140+ employees), and the Jena, Germany production campus (350 employees, opened 2023 following a €200M+ investment) producing over 400 pharmaceutical products across vials, ampoules, pre-filled syringes, cartridges, and implants.

EVER Pharma generates revenue through two streams: (1) direct product sales of specialty generic injectables to hospitals, clinics, and healthcare professionals via wholly-owned commercial affiliates in key European markets (Austria, Germany, UK, France, Italy, Poland) and a network of distribution partners across 70+ countries spanning Asia-Pacific, the Middle East, CIS, Russia, Latin America, and North America; and (2) contract development and manufacturing organization (CDMO) services for third-party pharmaceutical companies, leveraging its sterile fill-finish capabilities for biologics up to BSL 2 and high-potency substances up to OEB 5. The company holds broad regulatory certifications including EU GMP, ISO 13485, ISO 14001, ANVISA, CFDA, PDMA, GCC, and RU-GMP, enabling global market access. Ownership remains with the Hillebrand family, and the company continues to invest in geographic expansion, new product authorizations, and ecosystem partnerships (including a minority investment in AI neurorehabilitation startup Nyra Health).

Short descriptiontext

EVER Pharma is a privately held, family-owned Austrian specialty pharmaceutical company developing, manufacturing, and selling differentiated injectable generics and CDMO services across neurology, oncology, anesthesia, and critical care in 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersUnterach, Austria
HQ citystring
Unterach
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable pharmaceuticals, specialty generic injectables, contract manufacturing (CDMO), neurology and oncology injectables, hospital injectables supply
Industry5 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Injectable Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Specialty Generic Pharmaceuticals
TypeOne Time License
Description

Development, manufacturing and sale of specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Products include Cerebrolysin, Dacepton (Apomorphine), Fulvestrant, Dexmedetomidine, Cabazitaxel, Pemetrexed, Azacitidin, Bortezomib, and testosterone products. Revenue from product sales to hospitals, clinics, and healthcare providers globally.

everpharma.com
2CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization services for sterile injectables including vials, ampoules, pre-filled syringes, cartridges, and implants. Services include formulation development, analytical testing, stability studies, and fill-finish manufacturing for third-party pharmaceutical companies.

everpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Infrastructure, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Cerebrolysin
Description

Product brand for neurological therapy products

everpharma.com
+2 more records
Core offering1 text field

EVER Pharma develops, manufactures, and globally distributes specialty generic injectable pharmaceuticals for neurology (Parkinson's disease treatments), oncology, anesthesia, and critical care, alongside a CDMO business offering contract development and aseptic fill-finish manufacturing of sterile injectables for third-party pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Eliminates need for refrigeration storage and transport for Fulvestrant
+3 more records
Product overview1 text field

EVER Pharma is a global pharmaceutical company specializing in neurology, critical care, anaesthesia, and oncology. The company operates as a specialty pharmaceutical manufacturer offering a portfolio of branded generic injectables combined with CDMO (Contract Development and Manufacturing Organization) services. The product portfolio includes neurological therapies such as Cerebrolysin® and the D-mine® therapy package (D-mine® Pump, D-mine® Pen, and Dacepton®/Apomorphine) for Parkinson's disease; oncology products including Fulvestrant, Azacitidin, Cabazitaxel, Pemetrexed, Bortezomib, and Trabectedin; and anesthesia/critical care products including Dexmedetomidine. The company also provides comprehensive CDMO services including contract development and contract manufacturing of sterile injectables. Products are developed in Austria and manufactured in EU GMP-certified facilities in Austria and Germany. Founded in 1934, EVER Pharma distributes products in over 70 countries through international affiliates.

Product and service12 records
1Cerebrolysin®
CategoryNeurology injectable pharmaceutical
Description

Neuropeptide injectable product for neurological disorders, sold to hospitals and healthcare providers as part of EVER Pharma's neurology portfolio.

2Dacepton® (Dopaceptin®, Apomorphine Hydrochloride)
CategoryNeurology injectable pharmaceutical
Description

Apomorphine hydrochloride injectable for Parkinson's disease administered via continuous subcutaneous infusion as part of the D-mine therapy package.

3D-mine® Pump
CategoryMedical device for drug delivery
Description

CE-approved portable micro-infusion pump for precise continuous subcutaneous drug delivery in Parkinson's disease patients, part of the D-mine therapy package.

4Fulvestrant EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Injectable antiestrogen for breast cancer treatment, first and only Fulvestrant in Europe approved for room temperature storage, eliminating cold-chain requirements.

5Dexmedetomidine EVER Pharma
CategoryAnesthesia and critical care injectable pharmaceutical
Description

Injectable anesthetic for procedural and ICU sedation, first and only Dexmedetomidine in Europe for both adult procedural sedation and ICU sedation.

6Azacitidin EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Oncology injectable for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, available in 100mg and 150mg vial presentations.

7Cabazitaxel EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Oncology injectable for metastatic castration-resistant prostate cancer using a single-vial formulation that avoids pre-dilution, reducing preparation time and wastage.

8Pemetrexed EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Liquid injectable for malignant pleural mesothelioma and non-small cell lung cancer, formulated as a ready-to-use liquid with room temperature storage.

9Bortezomib EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Liquid, ready-to-use injectable for multiple myeloma treatment, eliminating reconstitution steps.

10Trabectedin EVER Pharma
CategoryOncology injectable pharmaceutical
Description

Oncology injectable for soft tissue sarcoma, part of EVER Pharma's specialty oncology portfolio.

11Testosterone Enantate / Testosterone Undecanoat EVER Pharma
CategoryHormone replacement injectable pharmaceutical
Description

Injectable hormone replacement therapy products for testosterone deficiency, sold in European markets following EU marketing authorization.

12CDMO Services (Contract Development and Manufacturing)
CategoryContract pharmaceutical manufacturing services
Description

Contract Development and Manufacturing Organization services covering sterile fill-finish, aseptic processing, terminal sterilization, biologics up to BSL 2, high-potency substance handling up to OEB 5, and analytical and stability services across vials, ampoules, pre-filled syringes, cartridges, and implants, sold to third-party pharmaceutical companies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-10
Description

EVER Pharma sponsors the 'EVER Pharma Auditorium' at PMU's House D dedicated to pharmacy. The partnership includes joint research projects in product innovation and improvement, student industrial internships, and company facility visits for pharmacy students.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership with hospital purchasing organizations and healthcare institutions across Europe for specialty injectable pharmaceuticals including Azacitidin, Cabazitaxel, and Pemetrexed.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hikma is a UK-listed specialty pharmaceutical company with a large injectable generics business focused on oncology, anesthesia, and hospital injectables across the US, Europe, and MENA — directly comparable to EVER Pharma's specialty injectable generics portfolio and multi-region distribution model.

TypeDirect peer
Description

Stada is a European-focused specialty generics and consumer health company with strong positions in CNS, oncology, and injectable specialty products, making it a close peer in geography, therapeutic mix, and product type to EVER Pharma.

TypeDirect peer
Description

Gland Pharma is an India-based pure-play sterile injectable manufacturer supplying regulated markets, now owned by Sanofi. Its focus on small-molecule and complex injectable manufacturing for global generics aligns closely with EVER Pharma's specialty injectable model and CDMO ambitions.

TypeDirect peer
Description

Polpharma is a Central European pharmaceutical manufacturer with portfolio breadth in generics, specialty injectables, and active pharmaceutical ingredients — a comparable mid-sized, regionally rooted European specialty pharma company with hospital-channel focus.

TypeDirect peer
Description

Vetter is a German-headquartered CDMO specializing in aseptic fill-finish of sterile injectables, including pre-filled syringes and complex biologics — directly comparable to EVER Pharma Jena's CDMO offering in capabilities, customer base, and regulatory profile.

TypeDirect peer
Description

Apotex is a Canadian private/generic pharmaceutical manufacturer with an injectable portfolio and international affiliates — a peer along generics manufacturing scale and multi-region commercial footprint, similar to EVER Pharma's Formative Pharma Canada and broader distribution.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is the world's largest generic injectable player post-2023 spin-off, with broad portfolio overlap in oncology and hospital injectables — a broad incumbent competing with EVER Pharma across multiple molecules, though at far greater scale and across more geographies.

TypeBroad incumbent
Description

Teva is a global generics giant with significant sterile injectable and CNS franchise — a broad incumbent overlapping EVER Pharma's specialty injectable and neurology positioning, but operating at far larger scale with broader therapeutic coverage.

TypeBroad incumbent
Description

Catalent is a leading global CDMO with major sterile injectable fill-finish capabilities, now part of Novo Holdings — a broad incumbent competing for the same third-party sterile injectable CDMO contracts EVER Pharma Jena is targeting.

TypeEmerging player
Description

Aenova is a European CDMO with sterile injectable capabilities targeting pharmaceutical companies, comparable to EVER Pharma Jena's CDMO services but with a narrower specialty injectable focus relative to EVER's broader portfolio offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries16 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EVER Pharma

Specialty Injectable Pharmaceuticalseverpharma.com

EVER Pharma is a privately held, family-owned Austrian specialty pharmaceutical company developing, manufacturing, and selling differentiated injectable generics and CDMO services across neurology, oncology, anesthesia, and critical care in 70+ countries.

What EVER Pharma does

EVER Pharma is a privately held, family-owned specialty pharmaceutical company founded in 1934 and headquartered in Unterach, Austria. The company develops, manufactures, and commercializes a portfolio of branded specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Its product range includes differentiated formulations such as room-temperature-stable Fulvestrant (the first in Europe), ready-to-use liquid Bortezomib, single-vial Cabazitaxel, and a complete Parkinson's disease therapy package combining Apomorphine (Dacepton) with proprietary micro-infusion devices (D-mine Pump, D-mine Pen). Manufacturing is concentrated in two EU GMP-certified facilities: the Unterach headquarters and R&D center (140+ employees), and the Jena, Germany production campus (350 employees, opened 2023 following a €200M+ investment) producing over 400 pharmaceutical products across vials, ampoules, pre-filled syringes, cartridges, and implants.

EVER Pharma generates revenue through two streams: (1) direct product sales of specialty generic injectables to hospitals, clinics, and healthcare professionals via wholly-owned commercial affiliates in key European markets (Austria, Germany, UK, France, Italy, Poland) and a network of distribution partners across 70+ countries spanning Asia-Pacific, the Middle East, CIS, Russia, Latin America, and North America; and (2) contract development and manufacturing organization (CDMO) services for third-party pharmaceutical companies, leveraging its sterile fill-finish capabilities for biologics up to BSL 2 and high-potency substances up to OEB 5. The company holds broad regulatory certifications including EU GMP, ISO 13485, ISO 14001, ANVISA, CFDA, PDMA, GCC, and RU-GMP, enabling global market access. Ownership remains with the Hillebrand family, and the company continues to invest in geographic expansion, new product authorizations, and ecosystem partnerships (including a minority investment in AI neurorehabilitation startup Nyra Health).

EVER Pharma firmographics

Firmographics
Name
EVER Pharma
Legal name
EVER Neuro Pharma GmbH
Website
https://everpharma.com
Company type
Private
Founded year
1934
Operating status
Operating
Headcount range
501–1,000 employees
Short description
EVER Pharma is a privately held, family-owned Austrian specialty pharmaceutical company developing, manufacturing, and selling differentiated injectable generics and CDMO services across neurology, oncology, anesthesia, and critical care in 70+ countries.
Ownership category
akta.pro rank

EVER Pharma industry classification

Industry
Product category
Specialty Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Sterile injectable pharmaceuticals
  • Specialty generic injectables
  • Contract manufacturing (CDMO)
  • Neurology and oncology injectables
  • Hospital injectables supply

Where EVER Pharma is headquartered

Location

Headquarters

HQ city
Unterach
HQ country
Austria
HQ region
Europe

Offices12 records

Markets served

EVER Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Infrastructure, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Specialty Generic Pharmaceuticals: Development, manufacturing and sale of specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Products include Cerebrolysin, Dacepton (Apomorphine), Fulvestrant, Dexmedetomidine, Cabazitaxel, Pemetrexed, Azacitidin, Bortezomib, and testosterone products. Revenue from product sales to hospitals, clinics, and healthcare providers globally.
  2. CDMO Services: Contract development and manufacturing organization services for sterile injectables including vials, ampoules, pre-filled syringes, cartridges, and implants. Services include formulation development, analytical testing, stability studies, and fill-finish manufacturing for third-party pharmaceutical companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

EVER Pharma product offering

Product offering

Core offering

EVER Pharma develops, manufactures, and globally distributes specialty generic injectable pharmaceuticals for neurology (Parkinson's disease treatments), oncology, anesthesia, and critical care, alongside a CDMO business offering contract development and aseptic fill-finish manufacturing of sterile injectables for third-party pharmaceutical companies.

Product overview

EVER Pharma is a global pharmaceutical company specializing in neurology, critical care, anaesthesia, and oncology. The company operates as a specialty pharmaceutical manufacturer offering a portfolio of branded generic injectables combined with CDMO (Contract Development and Manufacturing Organization) services. The product portfolio includes neurological therapies such as Cerebrolysin® and the D-mine® therapy package (D-mine® Pump, D-mine® Pen, and Dacepton®/Apomorphine) for Parkinson's disease; oncology products including Fulvestrant, Azacitidin, Cabazitaxel, Pemetrexed, Bortezomib, and Trabectedin; and anesthesia/critical care products including Dexmedetomidine. The company also provides comprehensive CDMO services including contract development and contract manufacturing of sterile injectables. Products are developed in Austria and manufactured in EU GMP-certified facilities in Austria and Germany. Founded in 1934, EVER Pharma distributes products in over 70 countries through international affiliates.

Differentiator

Problem solved

Functional benefit

Brands

  • Cerebrolysin: Product brand for neurological therapy products
  • Dacepton
  • D-mine

Products and services

  • Cerebrolysin® Neuropeptide injectable product for neurological disorders, sold to hospitals and healthcare providers as part of EVER Pharma's neurology portfolio.
  • Dacepton® (Dopaceptin®, Apomorphine Hydrochloride) Apomorphine hydrochloride injectable for Parkinson's disease administered via continuous subcutaneous infusion as part of the D-mine therapy package.
  • D-mine® Pump CE-approved portable micro-infusion pump for precise continuous subcutaneous drug delivery in Parkinson's disease patients, part of the D-mine therapy package.
  • Fulvestrant EVER Pharma Injectable antiestrogen for breast cancer treatment, first and only Fulvestrant in Europe approved for room temperature storage, eliminating cold-chain requirements.
  • Dexmedetomidine EVER Pharma Injectable anesthetic for procedural and ICU sedation, first and only Dexmedetomidine in Europe for both adult procedural sedation and ICU sedation.
  • Azacitidin EVER Pharma Oncology injectable for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, available in 100mg and 150mg vial presentations.
  • Cabazitaxel EVER Pharma Oncology injectable for metastatic castration-resistant prostate cancer using a single-vial formulation that avoids pre-dilution, reducing preparation time and wastage.
  • Pemetrexed EVER Pharma Liquid injectable for malignant pleural mesothelioma and non-small cell lung cancer, formulated as a ready-to-use liquid with room temperature storage.
  • Bortezomib EVER Pharma Liquid, ready-to-use injectable for multiple myeloma treatment, eliminating reconstitution steps.
  • Trabectedin EVER Pharma Oncology injectable for soft tissue sarcoma, part of EVER Pharma's specialty oncology portfolio.
  • Testosterone Enantate / Testosterone Undecanoat EVER Pharma Injectable hormone replacement therapy products for testosterone deficiency, sold in European markets following EU marketing authorization.
  • CDMO Services (Contract Development and Manufacturing) Contract Development and Manufacturing Organization services covering sterile fill-finish, aseptic processing, terminal sterilization, biologics up to BSL 2, high-potency substance handling up to OEB 5, and analytical and stability services across vials, ampoules, pre-filled syringes, cartridges, and implants, sold to third-party pharmaceutical companies.

Quantifiable outcome

  • Eliminates need for refrigeration storage and transport for Fulvestrant
  • +3 more outcomes

Companies that use EVER Pharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

EVER Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

EVER Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Paracelsus Medical Private University (PMU)coreStrategic or Co-development Partner · 10 September 2020EVER Pharma sponsors the 'EVER Pharma Auditorium' at PMU's House D dedicated to pharmacy. The partnership includes joint research projects in product innovation and improvement, student industrial internships, and company facility visits for pharmacy students.
  • Healthcare InstitutionscoreChannel Partner/ Reseller/ DistributorDistribution partnership with hospital purchasing organizations and healthcare institutions across Europe for specialty injectable pharmaceuticals including Azacitidin, Cabazitaxel, and Pemetrexed.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

EVER Pharma competitors and assessment

Company assessment

Direct peers

  • Hikma Pharmaceuticals: Hikma is a UK-listed specialty pharmaceutical company with a large injectable generics business focused on oncology, anesthesia, and hospital injectables across the US, Europe, and MENA — directly comparable to EVER Pharma's specialty injectable generics portfolio and multi-region distribution model.
  • Stada Arzneimittel: Stada is a European-focused specialty generics and consumer health company with strong positions in CNS, oncology, and injectable specialty products, making it a close peer in geography, therapeutic mix, and product type to EVER Pharma.
  • Gland Pharma: Gland Pharma is an India-based pure-play sterile injectable manufacturer supplying regulated markets, now owned by Sanofi. Its focus on small-molecule and complex injectable manufacturing for global generics aligns closely with EVER Pharma's specialty injectable model and CDMO ambitions.
  • Polpharma Group: Polpharma is a Central European pharmaceutical manufacturer with portfolio breadth in generics, specialty injectables, and active pharmaceutical ingredients — a comparable mid-sized, regionally rooted European specialty pharma company with hospital-channel focus.
  • Vetter Pharma: Vetter is a German-headquartered CDMO specializing in aseptic fill-finish of sterile injectables, including pre-filled syringes and complex biologics — directly comparable to EVER Pharma Jena's CDMO offering in capabilities, customer base, and regulatory profile.
  • Apotex: Apotex is a Canadian private/generic pharmaceutical manufacturer with an injectable portfolio and international affiliates — a peer along generics manufacturing scale and multi-region commercial footprint, similar to EVER Pharma's Formative Pharma Canada and broader distribution.

Broad incumbents

  • Sandoz (Novartis): Sandoz is the world's largest generic injectable player post-2023 spin-off, with broad portfolio overlap in oncology and hospital injectables — a broad incumbent competing with EVER Pharma across multiple molecules, though at far greater scale and across more geographies.
  • Teva Pharmaceutical Industries: Teva is a global generics giant with significant sterile injectable and CNS franchise — a broad incumbent overlapping EVER Pharma's specialty injectable and neurology positioning, but operating at far larger scale with broader therapeutic coverage.
  • Catalent: Catalent is a leading global CDMO with major sterile injectable fill-finish capabilities, now part of Novo Holdings — a broad incumbent competing for the same third-party sterile injectable CDMO contracts EVER Pharma Jena is targeting.

Emerging players

  • Aenova Group: Aenova is a European CDMO with sterile injectable capabilities targeting pharmaceutical companies, comparable to EVER Pharma Jena's CDMO services but with a narrower specialty injectable focus relative to EVER's broader portfolio offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

EVER Pharma social profiles

Digital presence

EVER Pharma compliance and trust

Trust signal

Compliance9 records

EVER Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EVER Pharma leadership team

Management profile

Number of profiles

Profiles7 records

EVER Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries16 records

EVER Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EVER Pharma M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EVER Pharma

What does EVER Pharma do?

EVER Pharma develops, manufactures, and globally distributes specialty generic injectable pharmaceuticals for neurology (Parkinson's disease treatments), oncology, anesthesia, and critical care, alongside a CDMO business offering contract development and aseptic fill-finish manufacturing of sterile injectables for third-party pharmaceutical companies.

Is EVER Pharma a public or private company?

EVER Pharma is a private company. It is classified as family owned and is currently operating.

When was EVER Pharma founded?

EVER Pharma was founded in 1934. It employs 501 to 1,000 people.

Where is EVER Pharma based?

EVER Pharma is headquartered in Unterach, Austria, in the Europe region.

How does EVER Pharma make money?

Two revenue lines are on record. Specialty Generic Pharmaceuticals are the primary driver. The others are CDMO Services.

Who are EVER Pharma's main competitors?

Direct peers on record are Hikma Pharmaceuticals, Stada Arzneimittel, Gland Pharma, Polpharma Group, Vetter Pharma and Apotex. Broad incumbents are Sandoz (Novartis), Teva Pharmaceutical Industries and Catalent. Aenova Group is listed as an emerging player.

Does EVER Pharma have an API?

No public API is recorded for EVER Pharma.

What industry is EVER Pharma in?

EVER Pharma's product category is Specialty Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comPeptide Therapeutics Market (2026) | GLP-1 Drugs, FDA Approvals 2026, Peptide Drugs, R&D Expansion, Global Growth 2026 | Top Companies 2026 - Ever Neuro Pharma GmbH, Novo Nordisk AS., Pfizer IncDataM Intelligence released a market research report on the global peptide therapeutics market in 2026, highlighting expected FDA reversals of restrictions on 14 injectable peptides and surging demand for GLP-1 therapies, with over 1 in 8 Americans using metabolic treatments. Several major pharmaceutical M&A and licensing deals were reported, including Eli Lilly's $7.8 billion acquisition of Centessa Pharmaceuticals (March 2026), Novartis's up to $1.7 billion licensing deal with Unnatural Products (February 2026), and Novo Nordisk's up to $2.1 billion partnership with Vivtex for oral peptide delivery technology (February 2026). Johnson & Johnson received FDA approval for ICOTYDETM (icotrokinra) in March 2026, the first oral IL-23 receptor-targeting peptide for plaque psoriasis, while the market is projected to grow at a CAGR of 7.8% between 2024 and 2031.Business Wire BlogEVER Pharma Launches the User-friendly D-mine® Pump Generated Report “DATA-mine®” to Enhance the Therapy Management of Parkinson’s Patients on ApomorphineEVER Pharma launched DATA-mine REPORT, a tool to read D-mine Pump data into PDF reports for healthcare professionals. The report displays infusion therapy parameters like dosing, flow rates, and time settings in tables and graphs. The company aims to optimize therapy management for Parkinson's patients on apomorphine.Business Wire BlogEVER Pharma Launches a Digital Training App for the D-mine® PumpEVER Pharma launched a digital training app for its D-mine Pump, an infusion device for Parkinson's patients. The app is a simulation tool for healthcare professionals and caregivers, available on Android and iOS devices. EVER Pharma markets the product in over 80 countries.